Skip to Main Content

1.2.8: Develop and implement individualized treatment plans, taking into consideration contraindications, warnings, and precautions

What is the parenteral asthma medication contraindicated in patients with a corn allergy?

(A) Prednisone

(B) Theophylline

(C) Budesonide

(D) Omalizumab

The Correct Answer is: B

Theophylline (B) is contraindicated in patients with a corn allergy. The premixed injection may contain corn-derived dextrose.

Prednisone (A), budesonide (C), and omalizumab (D) are not contraindicated in patients with a corn allergy.

Which of the following conditions would be a contraindication to administration of tamoxifen for the prevention of breast cancer in a "high-risk" premenopausal patient?

(A) History of deep venous thrombosis

(B) First-degree relative with ER negative breast cancer

(C) History of diabetes mellitus

(D) History of seizures

The Correct Answer is: A

Tamoxifen is associated with an increased risk for developing thromboembolic events. Administration of tamoxifen to prevent breast cancer is contraindicated in patients with a history of deep venous thrombosis (A) or pulmonary emboli.

The estrogen receptor status of first-degree relatives is not a contraindication to prescribing tamoxifen to reduce the risk of developing breast cancer (B). Diabetes mellitus (C) is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer. A history of seizures (D) is not a contraindication to prescribing tamoxifen to reduce the risk for developing breast cancer.

Which of the following conditions would be a contraindication for prescribing an aromatase inhibitor?

(A) The development of arthralgias and myalgias

(B) A patient with a history of thromboembolic events

(C) A premenopausal patient

(D) A postmenopausal patient with a history of thromboembolic events

The Correct Answer is: C

The administration of aromatase inhibitors to premenopausal women (C) with breast cancer is contraindicated because they are ineffective in depleting estrogen production in women with functioning ovaries.

Arthralgias and myalgias (A) are documented adverse effects of aromatase inhibitors. If a patient develops these toxicities, a trial of an alternative aromatase inhibitor is indicated. A patient with a history of thromboembolic events (B) is not a contraindication for administration of aromatase inhibitors. The administration of aromatase inhibitors are not contraindicated for postmenopausal patients with a history of thromboembolic events (D).

Topic: Breast cancer

Aldosterone antagonists should be avoided in ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.